New Delhi: In a fresh drug pricing move, the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has fixed the retail prices of 11 drug formulations, covering medicines used in the management of diabetes, hypertension, and pain.
The prices have been notified through S.O. 4774(E), dated August 27, 2026, in exercise of powers conferred under paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order (DPCO), 2013. The retail prices specified by the pricing regulator are exclusive of Goods and Services Tax (GST), if any

The formulations brought under retail price fixation include medicines used for the management of diabetes, hypertension, pain and muscle spasm, psychiatric conditions and HIV infection, among other therapeutic indications.

Also Read:NPPA Proposes Making Drugmakers Solely Liable for Overpricing Essential Medicines: Report

The formulations include Drotaverine Hydrochloride 80 mg and Mefenamic Acid 250 mg Tablets at Rs 14.59 per tablet by Innova Captab Ltd./Zorvia Healthcare Ltd.; Empagliflozin 10 mg, Linagliptin 5 mg and Metformin Hydrochloride 1000 mg Extended-Release Tablets at Rs 12.27 per tablet and Empagliflozin 25 mg, Linagliptin 5 mg and Metformin Hydrochloride 1000 mg Extended-Release Tablets at Rs 14.33 per tablet, both by Exemed Pharmaceuticals/Macleods Pharmaceuticals Ltd.; and Escitalopram 10 mg and Clonazepam 0.5 mg Mouth Dissolving Tablets at Rs 15.69 per tablet by Akums Drugs & Pharmaceuticals Ltd./Mankind Pharma Ltd.

Further, NPPA has fixed the retail price of Glimepiride 3 mg Tablets at Rs 12.48 per tablet and Glimepiride 4 mg Tablets at Rs 13.47 per tablet, both manufactured by Unison Pharmaceuticals Pvt. Ltd.; Telmisartan 40 mg and Amlodipine 5 mg Tablets at Rs 13.08 per tablet and Telmisartan 40 mg and Chlorthalidone 12.5 mg Tablets at Rs 13.27 per tablet, both by Pure and Cure Healthcare Pvt. Ltd./Sun Pharmaceutical Industries Ltd.

The price regulator has also fixed the retail price of Thiocolchicoside 4 mg, Aceclofenac 100 mg and Paracetamol 325 mg Tablets at Rs 19.74 per tablet by Ravenbhel Healthcare Pvt. Ltd./Seagull Pharmaceuticals Pvt. Ltd.; Voglibose 0.3 mg and Metformin Hydrochloride 500 mg Sustained-Release Tablets at Rs 13.55 per tablet by Pure and Cure Healthcare Pvt. Ltd./Alkem Wellness Ltd.; and Dolutegravir 50 mg, Lamivudine 300 mg and Tenofovir Alafenamide 25 mg Tablets at Rs 120.07 per tablet by Emcure Pharmaceuticals Ltd.
Also Read:NPPA Sets Retail Prices for Cipla, German Remedies Drug Combinations
The notification stated,
In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 and S.O. 3516(E) dated 30th June, 2026 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) has fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Sl. No.

Name of the Formulation / Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail Price (₹)

(1)

(2)

(3)

(4)

(5)

(6)

1

Drotaverine Hydrochloride and Mefenamic Acid Tablets

Each film coated tablet contains: Drotaverine Hydrochloride IP 80 mg, Mefenamic Acid IP 250 mg

1 Tablet

M/s Innova Captab Ltd./ M/s Zorvia Healthcare Ltd.

14.59

2

Empagliflozin, Linagliptin and Metformin Hydrochloride Extended-Release Tablets

Each film coated bilayer tablet contains: Empagliflozin 10 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Exemed Pharmaceuticals/ M/s Macleods Pharmaceuticals Ltd.

12.27

3

Empagliflozin, Linagliptin and Metformin Hydrochloride Extended-Release Tablets

Each film coated bilayer tablet contains: Empagliflozin 25 mg, Linagliptin 5 mg, Metformin Hydrochloride IP 1000 mg (as Extended Release)

1 Tablet

M/s Exemed Pharmaceuticals/ M/s Macleods Pharmaceuticals Ltd.

14.33

4

Escitalopram Oxalate and Clonazepam Mouth Dissolving Tablets

Each Mouth Dissolving tablet contains: Escitalopram Oxalate IP eq. to Escitalopram 10 mg, Clonazepam IP 0.5 mg

1 Tablet

M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Mankind Pharma Ltd.

15.69

5

Glimepiride Tablets

Each uncoated tablet contains: Glimepiride IP 3 mg

1 Tablet

M/s Unison Pharmaceuticals Pvt. Ltd.

12.48

6

Glimepiride Tablets

Each uncoated tablet contains: Glimepiride IP 4 mg

1 Tablet

M/s Unison Pharmaceuticals Pvt. Ltd.

13.47

7

Telmisartan and Amlodipine Tablets

Each uncoated bilayered tablet contains: Telmisartan IP 40 mg, Amlodipine Besilate IP eq. Amlodipine 5 mg

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Sun Pharmaceutical Industries Ltd.

13.08

8

Telmisartan and Chlorthalidone Tablets

Each film coated tablet contains: Telmisartan IP 40 mg, Chlorthalidone IP 12.5 mg

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Sun Pharmaceutical Industries Ltd.

13.27

9

Thiocolchicoside, Aceclofenac & Paracetamol Tablets

Each film coated tablet contains: Thiocolchicoside IP 4 mg, Aceclofenac IP 100 mg, Paracetamol IP 325 mg

1 Tablet

M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Seagull Pharmaceuticals Pvt. Ltd.

19.74

10

Voglibose and Metformin Hydrochloride (SR) Tablets

Each uncoated bilayered tablet contains: Voglibose IP 0.3 mg, Metformin Hydrochloride IP 500 mg (as sustained release)

1 Tablet

M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Alkem Wellness Ltd.

13.55

11

Dolutegravir, Lamivudine and Tenofovir Alafenamide Tablets

Each film coated tablet contains: Lamivudine IP 300 mg, Tenofovir Alafenamide Fumarate IP eq. to Tenofovir Alafenamide 25 mg, Dolutegravir Sodium IP eq. to Dolutegravir 50 mg

1 Tablet

M/s Emcure Pharmaceuticals Ltd.

120.07

Further, the notice added,

(a) The manufacturer, as mentioned in column (5) of the table above, of formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price not exceeding the price as specified in column (6) of the table above.
(b) Any other existing manufacturer launching the same new drug as specified in column (2), (3) and (4) of table above within twelve months of the date of publication of this notification in the Official Gazette is permitted to do so at a retail price not exceeding the price as specified in column (6) of the table above subject to filing of Form-IA on IPDMS 2.0 along with supporting documents within one month of launch.
(c) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
(d) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
To view the official notice, click the link below:
https://medicaldialogues.in/pdf_upload/2026/08/31/retail-27-08-2026-473494.pdf
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Susmita Roy

Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .